Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

IF 27.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Cancer Pub Date : 2024-11-12 DOI:10.1186/s12943-024-02166-w

Qi Xie, Xiaolin Liu, Rengyun Liu, Jingxuan Pan, Jing Liang

引用次数: 0

Abstract

PD-1/PD-L1 blockade therapies have displayed extraordinary clinical efficacy for melanoma, renal, bladder and lung cancer; however, only a minority of colorectal cancer (CRC) patients benefit from these treatments. The efficacy of PD-1/PD-L1 blockade in CRC is limited by the complexities of tumor microenvironment. PD-1/PD-L1 blockade immunotherapy is based on T cell-centered view of tumor immunity. However, the onset and maintenance of T cell responses and the development of long-lasting memory T cells depend on innate immune responses. Acknowledging the pivotal role of innate immunity in anti-tumor immune response, this review encapsulates the employment of combinational therapies those involve PD-1/PD-L1 blockade alongside the activation of innate immunity and explores the underlying cellular mechanisms, aiming to harnessing innate immune responses to induce long-lasting tumor control for CRC patients who received PD-1/PD-L1 blockade therapy.

查看原文本刊更多论文

先天性免疫激活与 PD-1/PD-L1 阻断相结合治疗结直肠癌的细胞机制

PD-1/PD-L1阻断疗法对黑色素瘤、肾癌、膀胱癌和肺癌显示出非凡的临床疗效；然而，只有少数结直肠癌（CRC）患者能从这些疗法中获益。由于肿瘤微环境的复杂性，PD-1/PD-L1 阻断疗法对 CRC 的疗效受到了限制。PD-1/PD-L1 阻断免疫疗法是基于以 T 细胞为中心的肿瘤免疫观点。然而，T 细胞应答的发生和维持以及长效记忆 T 细胞的形成都依赖于先天性免疫应答。鉴于先天性免疫在抗肿瘤免疫反应中的关键作用，本综述总结了在激活先天性免疫的同时使用 PD-1/PD-L1 阻断的联合疗法，并探讨了其潜在的细胞机制，旨在利用先天性免疫反应为接受 PD-1/PD-L1 阻断疗法的 CRC 患者诱导持久的肿瘤控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Cancer 医学-生化与分子生物学

CiteScore

54.90

自引率

2.70%

发文量

224

审稿时长

2 months

期刊介绍： Molecular Cancer is a platform that encourages the exchange of ideas and discoveries in the field of cancer research, particularly focusing on the molecular aspects. Our goal is to facilitate discussions and provide insights into various areas of cancer and related biomedical science. We welcome articles from basic, translational, and clinical research that contribute to the advancement of understanding, prevention, diagnosis, and treatment of cancer. The scope of topics covered in Molecular Cancer is diverse and inclusive. These include, but are not limited to, cell and tumor biology, angiogenesis, utilizing animal models, understanding metastasis, exploring cancer antigens and the immune response, investigating cellular signaling and molecular biology, examining epidemiology, genetic and molecular profiling of cancer, identifying molecular targets, studying cancer stem cells, exploring DNA damage and repair mechanisms, analyzing cell cycle regulation, investigating apoptosis, exploring molecular virology, and evaluating vaccine and antibody-based cancer therapies. Molecular Cancer serves as an important platform for sharing exciting discoveries in cancer-related research. It offers an unparalleled opportunity to communicate information to both specialists and the general public. The online presence of Molecular Cancer enables immediate publication of accepted articles and facilitates the presentation of large datasets and supplementary information. This ensures that new research is efficiently and rapidly disseminated to the scientific community.